



Figure S1 Changes of GLS between cardiac injury and non-cardiac injury groups. GLS, global longitudinal strain.

Table S1 Lower limit of left ventricular ejection fraction (5th percentile)

Body surface area (m ²)	5th percentile
0.25–0.3	56.048
0.31–0.4	56.792
0.41–0.5	57.852
0.51–0.6	59.018
0.61–0.7	58.617
0.71–0.8	58.634
0.81–0.9	57.023
0.91–1	58.368
1.01–1.1	58.439
1.11–1.2	57.467
1.21–1.3	56.316
1.31–1.4	54.769

Table S2 Characteristics of the study population by different disease group

Variables	ALL (n=7)	AML (n=7)	vsAA (n=14)	PKD (n=1)
Age (years)	7.00±4.08	6.43±4.16	8.29±3.65	4.00
Gender (male)	6 (85.71)	3 (42.86)	8 (57.14)	0
Height (cm)	122.21±20.76	119.14±26.53	135.93±23.27	105.00
Weight (kg)	26.29±10.53	25.14±11.93	34.25±15.40	18.00
Body surface area unit (m ²)	0.94±0.27	0.90±0.31	1.12±0.35	0.73
Prior anthracyclines dose (mg/m ²)	132.86±24.30	180.00±28.28	–	–
GLS—before medication (%)	–20.44±2.33	–20.39±3.20	–20.01±2.29	–21.70
GLS—1 day after cyclophosphamide chemotherapy (%)	–18.90±1.77	–19.13±2.42	–19.79±1.48	–20.80
GCS—before medication (%)	–19.44±2.63	–22.28±1.52	–22.89±2.68	–21.80
GCS—1 day after cyclophosphamide chemotherapy (%)	–19.96±3.57	–21.24±2.72	–23.35±3.49	–17.80
PR interval—before medication (ms)	138.17±18.80	129.43±17.30	133.64±19.48	142.00
QRS interval—before medication (ms)	80.50±2.66	79.71±5.28	87.00±6.35	72.00
QT interval—before medication (ms)	347.50±36.54	333.00±55.52	353.50±42.31	308.00
Troponin T—before medication (pg/mL)	9.63±4.80	10.40±5.58	5.15±1.87	3.00
Coagulated D-dimer—before medication (mg/L)	0.40±0.19	0.91±1.10	2.66±2.79	0.59
PR interval—1 day after cyclophosphamide chemotherapy (ms)	137.14±13.11	135.71±19.31	133.57±11.04	137.00
QRS interval—1 day after cyclophosphamide chemotherapy (ms)	80.57±4.54	79.43±4.65	84.43±7.21	81.00
QT interval—1 day after cyclophosphamide chemotherapy (ms)	326.57±37.50	333.57±63.80	348.14±43.37	304.00
Troponin T—1 day after cyclophosphamide chemotherapy	8.16±7.01	10.15±6.39	4.01±0.85	4.02
Coagulated D-dimer—1 day after cyclophosphamide chemotherapy	1.21±1.21	0.71±0.33	1.08±1.17	1.06

Data are presented as n (%) or mean ± standard deviation. PR intervals: from the start of the P wave to the start of QRS; QRS interval: from the beginning of a Q wave to the termination of an S wave; QT interval: from QRS onset to T-wave offset. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; vsAA, very severe aplastic anemia; PKD, pyruvate kinase deficiency; GLS, global longitudinal strain; GCS, global circumferential strain.